RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
Brief description of study
The main goal of this phase III clinical trial is to study how well erlotinib (an EGF receptor kinase inhibitor) with adjuvant therapy versus a placebo (an inactive drug) works in improving overall survival for patients with completely resected stage IB-IIIA EGFR mutant type non-small cell lung cancer
Clinical Study Identifier: s16-02079
ClinicalTrials.gov Identifier: NCT02193282
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
